A transition plan developed for the ENGAGE-AF TIMI 48 trial was associated with reduced excess thrombotic and bleeding events in patients moved from one oral anticoagulant to another. In the ...

Anticoagulants Verseon has submitted the Phase I protocol for its lead precision oral anticoagulant (PROAC) candidate, VE-1902, and expects to start first-in-human trials in Q3 2018.